| The following article features coverage from the American Society of Clinical Oncology 2019 meeting. Click here to read more of Hematology Advisor’s conference coverage. |
Treatment for newly diagnosed multiple myeloma (MM) with daratumumab, lenalidomide, and dexamethasone (D-Rd) may be associated with improved health-related quality of life compared with lenalidomide and dexamethasone (Rd) alone.
Researchers presented interim data from the ongoing phase 3 MAIA trial (ClinicalTrials.gov Identifier: NCT02252172) at the 2019 American Society for Clinical Oncology Annual Meeting in Chicago, Illinois. In this study, patients with newly diagnosed MM received D-Rd (368 patients) or Rd (369 patients) and completed 2 questionnaires that assessed quality of life and survival at baseline and every 3 months thereafter.
In both groups, compliance was higher than 90% at baseline and higher than 80% at 12 months. Patients in the D-Rd cohort experienced significantly greater improvement in Global Health Status (least square [LS] mean change, 4.5 vs 1.5; P =.0454) and the EQ-5D-5L Visual Analog Scale (LS mean change, 10.1 vs 4.9; P =.0002) compared with patients in the Rd cohort.
Continue Reading
Additionally, according to the EQ-5D-5L questionnaire, patients receiving daratumumab experienced a median time to worsening 10 months longer than that experienced by patients receiving daratumumab compared with patients receiving Rd alone.
Both treatment groups experienced a decline in cognitive functioning, though no statistically significant difference was found between the groups. Patients in the D-Rd cohort reported significantly less pain early (LS mean change, -17.9 vs -11.0; P =.0007).
The researchers concluded that D-Rd treatment yielded more rapid, long-term improvement in quality of life for patients with newly diagnosed MM.
Reference
1. Perrot A, Faco T, Plesner T, et al. Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA. Presented at: 2019 ASCO Annual Meeting; June 3, 2019; Chicago, IL. Abstract 8016.
